{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"}]}],"title":">=1 AdEERs possibly related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"}]}],"title":"Discontinued due to AE possibly related to drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Died on therapy possibly related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Died within 31 days of last dose of drug PRSD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"AdEERS= Adverse Event Expedited Reporting System; AE = adverse event. Patients may be counted in more than 1 category. Includes events that were considered possibly related to study drug (PRSD) as judged by the investigator.","groups":[{"description":"Pemetrexed 1910 milligrams per meters squared (mg/m\\^2) (or 60 milligrams per kilogram \\[mg/kg\\] if patient \\<12 months old)","id":"OG000","title":"Osteosarcoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG001","title":"Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG002","title":"Rhabdomyosarcoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG003","title":"Neuroblastoma (Measureable Disease)"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG004","title":"Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG005","title":"Ependymoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG006","title":"Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG007","title":"Non-Brainstem High-Grade Glioma"}],"paramType":"NUMBER","populationDescription":"All treated participants.","reportingStatus":"POSTED","timeFrame":"every cycle (up to 2 years and 7 months)","title":"Number of Patients With Adverse Events, Discontinuations, or Deaths Possibly Due to Study Drug","type":"SECONDARY","unitOfMeasure":"Participants"}